We are live on
!
Find out more
EAM
EULAV Asset Management Portfolio holdings
AUM
$3.13B
1-Year Est. Return
23.04%
This Fund
S&P 500
This Quarter
Est. Return
+2.34%
1 Year Est. Return
+23.04%
3 Year Est. Return
+90.7%
5 Year Est. Return
+115.08%
10 Year Est. Return
+583.23%
AUM
$3.79B
AUM Growth
+$6.57M
(+0.17%)
Cap. Flow
-$29.8M
Cap. Flow
% of AUM
-0.79%
Top 10 Holdings %
Top 10 Hldgs %
19.67%
Holding
225
New
3
Increased
32
Reduced
59
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$12.9M |
| 2 |
EXAS
Exact Sciences
EXAS
|
+$12.7M |
| 3 |
Delta Air Lines
DAL
|
+$6.94M |
| 4 |
ATVI
Activision Blizzard
ATVI
|
+$6.27M |
| 5 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$5.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ZEN
ZENDESK INC
ZEN
|
+$12.4M |
| 2 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$9.74M |
| 3 |
ANSS
Ansys
ANSS
|
+$8.61M |
| 4 |
Teledyne Technologies
TDY
|
+$7.42M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$6.64M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 34% |
| 2 | Healthcare | 17.11% |
| 3 | Industrials | 15.63% |
| 4 | Financials | 11.96% |
| 5 | Consumer Discretionary | 9.27% |
Similar funds
LFG
BI
GKWIM
DIG
BP
CCI
PC
TCG
EULAV Asset Management's Q3 2021 Portfolio in Review
As of Q3 2021, EULAV Asset Management held 225 positions worth $3.79B, up 0.17% from $3.78B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Trading was light in Q3 2021: portfolio turnover was 2.7%. EULAV Asset Management opened 3 new positions and exited 3, leaving the 225-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 34% of assets, down from 34% a quarter earlier, followed by Healthcare and Industrials.
- EULAV Asset Management's largest Q3 2021 buy was Edwards Lifesciences: 113,010 shares worth $12.8M.
- EULAV Asset Management added most to Exact Sciences in Q3 2021, an estimated $12.7M increase.
- EULAV Asset Management's biggest Q3 2021 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $9.74M.
- EULAV Asset Management fully exited ZENDESK INC in Q3 2021, selling an estimated $12.4M.
- EULAV Asset Management's ten largest holdings make up 20% of its $3.79B portfolio in Q3 2021.
- EULAV Asset Management opened 3 new positions and closed 3 in Q3 2021.
- EULAV Asset Management's portfolio value rose 0.17% quarter-over-quarter to $3.79B.
Based on EULAV Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.